Arcus Biosciences beat FY25 EPS/revenue estimates as Casdatifan drives upside; $1.01B cash funds Phase 3 into 2H28. Click for my latest analysis of RCUS stock.

Don't follow general market sentiment when it comes to these two stocks.

Investors in Cellectar Biosciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter. It's worth ...

PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 ...

Analysts anticipate Pulse Biosciences to report an earnings per share (EPS) of $-0.25. The announcement from Pulse ...

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks. TheFly reported on February ...

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also ...

Director Jeffrey Stein of IDEAYA Biosciences, Inc. NASDAQ:IDYA, recently purchased 50,000 shares of common stock. The transaction, which occurred on March 2, 2026, involved a total investment of $1.65 ...

Castle Biosciences, Inc. (CSTL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...